分子对接技术的进步,用于针对神经退行性疾病中的蛋白质错折
Kuldeep Singh1, Jeetendra Kumar Gupta1, Shiv Narayan2
1Department of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
Current pharmaceutical biotechnology
|February 20, 2025
概括
分子对接有助于通过准蛋白质误折叠来发现神经退行性疾病的药物. 这种计算方法有助于识别抑制阿尔茨海默病,帕金森病和亨廷顿病聚合的化合物.
科学领域:
- 计算化学是一种计算化学.
- 神经科学是一个神经科学.
- 药物发现 药物发现
背景情况:
- 像阿尔茨海默病,帕金森病和亨廷顿病这样的神经退行性疾病是一个主要的健康问题,治疗方法很少.
- 蛋白质错误折叠和聚合是这些疾病的关键病理特征,使它们成为治疗点.
- 分子对接是一种计算技术,用于识别可能干扰蛋白质错折的小分子.
研究的目的:
- 审查分子对接的最新进展,以针对神经退行性疾病中的蛋白质错折.
- 讨论分子对接在这个领域的原理,方法和应用.
- 突显神经退行性疾病研究中的分子对接的挑战和未来方向.
主要方法:
- 对分子对接原理,评分函数和算法进行审查.
- 整合分子动力学模拟和机器学习以提高对接精度.
- 分析结构生物学方法,如冷EM和X射线晶体学,以加强对接研究.
主要成果:
- 分子对接成功地确定了针对阿尔茨海默氏症 (粉样蛋白-β),帕金森氏症 (α-synuclein) 和亨廷顿氏症 (突变亨廷丁) 疾病中的蛋白质聚合的潜在药物候选者.
- 先进的计算技术,包括MD模拟和ML,提高对接研究的精度.
- 结构生物学方法提供补充数据来完善对接预测和验证发现.
结论:
- 分子对接是一种宝贵的工具,用于发现神经退行性疾病中蛋白质错折的治疗方法.
- 将对接与MD模拟,机器学习和实验验证相结合,对于成功的药物开发至关重要.
- 计算和结构生物学方法的不断进步将进一步提高分子对接在对抗神经退行性疾病的有效性.
更多相关视频
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429


